Diabetic Peripheral Neuropathy and ACT: A Clinical Deep Dive | ALIV

Diabetic peripheral neuropathy (DPN) — the nerve damage produced by sustained elevated blood glucose — affects approximately 50% of people with diabetes in India after ten or more years of the disease. The symptoms — burning, tingling, numbness, or painful sensations in the feet and hands — significantly impair quality of life, disrupt sleep, and in advanced cases, increase the risk of undetected foot injury leading to ulceration and amputation. Standard management (glycaemic control, pregabalin, duloxetine, vitamin B complex) manages symptoms but does not substantially reverse established neuropathic damage. ACT's neurotrophic and vascular growth factor delivery targets the biological mechanisms of DPN more directly than symptomatic pharmacological management.

The Biology of DPN and the ACT Target

DPN involves two interacting pathological processes: Neuronal metabolic damage: Sustained hyperglycaemia produces oxidative stress, advanced glycation end products (AGEs), and polyol pathway activation in peripheral neurons — collectively impairing neuronal energy metabolism, disrupting axonal transport, and reducing nerve conduction velocity. Vascular damage: Microvascular disease reduces blood supply to the vasa nervorum — the tiny vessels supplying peripheral nerves — producing ischaemic nerve damage. ACT's growth factor profile addresses both: IGF-1 and BDNF support neuronal metabolic function and axonal regeneration; VEGF promotes angiogenesis and restores the vasa nervorum blood supply; NGF (Nerve Growth Factor) — present in adipose-derived preparations — is the primary survival signal for small-diameter sensory nerve fibres (the fibres most affected in early DPN). This mechanistic alignment makes DPN one of the most compelling ACT indications in metabolic medicine. See: ACT for diabetes complications.

Clinical Expectations for DPN

DPN response to ACT is slower and more variable than musculoskeletal applications — nerve regeneration is a slow biological process, and the timeline for meaningful symptomatic improvement in neuropathy is six to twelve months post-procedure. The sequence most commonly observed: first, a reduction in pain and burning symptoms (as the inflammatory neuropathic component is addressed by the anti-inflammatory paracrine signals); later, improvement in sensory function (touch sensation, temperature discrimination) as nerve fibre repair progresses; and in some patients, improved nerve conduction velocity on neurophysiology testing at twelve months. Not all patients achieve measurable neurological improvement — those with very advanced DPN (complete sensory loss, significant structural axonal degeneration visible on skin punch biopsy) have limited residual nerve fibre populations for neurotrophic support to work upon.

Can ACT prevent diabetic foot ulceration?

In patients with DPN and established peripheral vascular disease, ACT's VEGF-driven angiogenic effect can meaningfully improve peripheral blood flow to the foot — potentially reducing the ischaemic component of foot ulceration risk alongside meticulous foot care. ACT is not a substitute for diabetic foot care (daily inspection, appropriate footwear, regular podiatry), but it addresses the vascular biology that makes the diabetic foot vulnerable in a way that foot care alone cannot. For patients with DPN and documented impaired peripheral circulation (reduced ABI — ankle-brachial index), the vascular component of ACT's benefit may be clinically significant.

Is glycaemic control a prerequisite for DPN ACT?

Yes — not perfect glycaemic control, but reasonable HbA1c (ideally below 8%) before proceeding with ACT. Ongoing severe hyperglycaemia (HbA1c above 10%) continues to produce the oxidative and glycation damage that ACT is trying to counteract — and delivering growth factor support into an environment of ongoing severe glycaemic toxicity significantly reduces the net regenerative benefit. Achieving the best achievable glycaemic control before ACT, then maintaining it through and after the course, is the clinical imperative for DPN applications.